The Texas Interprofessional Pharmacogenomics (IPGx)

The investigator's primary aim is to evaluate polypharmacy-associated adverse drug reactions (ADR) in a pilot study of at-risk patients using state-of-the-art pharmacogenomic technology and to use this information to make recommendations for optimization of pharmacotherapy regimens. The data from the pilot cohort will be used to optimize and integrate a customized electronic decision support (clinical semantic network; CSN) dashboard to identify drug regimens that should be modified, replaced, or discontinued. A secondary objective of the pilot study is to evaluate the capacity/saturation of CYP P450 enzymatic pathways in polypharmacy patients. A third objective is to determine the feasibility of the planned informatics workflows between the CLIA lab, the EMR, and the Family Medicine Practice.

NCT Number	NCT06219720
Lead Sponsor	Texas A&M University Collaborators: InnovativeGx, Texas A&M Health Family Care Clinic, iC42 Clinical Research and Development, Goldblatt systems
Conditions	Adverse Drug Reaction
Enrollment	50 participants
Start Date	2021-12-15
Primary Completion	2026-11 (estimated)
Study Completion	2027-11 (estimated)
Updated on ClinicalTrials.gov	2025-09-12